Nanoparticle Dual Attack on Oxidative Stress and Epigenetics Halts Joint Aging

Osteoarthritis (OA) affects hundreds of millions of people worldwide and currently has no approved disease-modifying therapy. A major reason treatments fail is that OA is driven by a self-reinforcing cycle: reactive oxygen species (ROS) damage chondrocytes, triggering epigenetic changes that amplify inflammation and senescence, which in turn generate more ROS. Addressing only one arm of this loop leaves the other intact. This study set out to break both arms simultaneously using a single injectable nanoparticle platform.

The researchers fabricated HPcLW nanoparticles (~250 nm) through electrostatic self-assembly of human serum albumin (HSA) and poly-L-lysine (PLL). PLL was conjugated to a PEG linker bearing a collagen II-binding peptide (CollBP) for cartilage targeting. This scaffold was co-loaded with lycopene—a potent carotenoid antioxidant with poor standalone bioavailability—and siRNA targeting WTAP, a core m6A RNA methyltransferase that the team previously identified as overexpressed in OA and aged cartilage (confirmed via GEO dataset GSE249509). The nanoparticles achieved lycopene encapsulation efficiencies above 80% and siRNA loading efficiencies above 92%, with pH-sensitive release (accelerated at pH 5.0 mimicking the acidic OA joint) and strong siRNA protection from RNase degradation (82.3% preserved after RNase A challenge).

In vitro and in vivo biosafety assessments showed no cytotoxicity in chondrocytes and no organ histopathology after two months of intra-articular injection in mice. Fluorescence tracking demonstrated joint retention for up to 10 days post-injection, a notable improvement over untargeted controls, attributed to the CollBP-mediated cartilage matrix anchoring.

Mechanistically, WTAP siRNA suppressed m6A methylation, downregulating PAI-1—a senescence-promoting target—while lycopene scavenged ROS and helped preserve siRNA integrity within the oxidative joint microenvironment. This dual action alleviated mitochondrial dysfunction, reduced senescence-associated secretory phenotype (SASP) markers, restored cartilage matrix proteins (COL2), and suppressed matrix-degrading enzymes (MMP13). In both surgically induced (DMM model) and naturally aged mouse models, HPcLW outperformed single-agent or non-targeted controls in halting cartilage degeneration.

The study establishes the WTAP/PAI-1 epigenetic axis as a tractable therapeutic target in OA and demonstrates that combining antioxidant and epigenetic strategies within a single cartilage-homing nanoparticle can synergistically dismantle the self-perpetuating senescence cycle. Limitations include reliance on mouse models, the absence of a specific small-molecule WTAP inhibitor comparison, and the need for longer-term safety and efficacy studies before clinical translation.